Primary ocular lymphoma: Clinical features, diagnosis, and treatment

Clinical Lymphoma

Volumn 4, Issue 1, 2003, Pages 22-29

  Hormigo, Adília ^a   DeAngelis, Lisa M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain tumor; Central nervous system lymphoma; Non Hodgkin's lymphoma; Uveitis; Vitreitis

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; THIOTEPA; VINCRISTINE;

BLEPHARITIS; CATARACT; CLINICAL FEATURE; CONJUNCTIVAL HYPEREMIA; DEMOGRAPHY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DIFFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; ECHOGRAPHY; EDEMA; ENDOPHTHALMITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFECTION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANGIOGRAPHY; HUMAN; KERATITIS; LACRIMAL GLAND DISEASE; LACRIMATION; MALE; NONHODGKIN LYMPHOMA; OPTIC NERVE ATROPHY; PATHOGENESIS; PATHOLOGY; PHOTOPHOBIA; PRIMARY INTRAOCULAR LYMPHOMA; RETINA DETACHMENT; RETINA MACULOPATHY; REVIEW; VITRECTOMY; VITREOUS BIOPSY; VITREOUS HEMORRHAGE; WHOLE BODY RADIATION;

EID: 0037677688     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.010     Document Type: Review

References (90)

1. Whitcup SM, Smet MD, Rubin BI, et al. Intraocular lymphoma: clinical and histopathologic diagnosis. Ophthalmology 1993; 100: 1399-1406.
2. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68:835-853.
3. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999; 43:199-201.
4. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends and epidemiology. Curr Opin Oncol 2001; 13:160-166.
5. Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States 1990-1994. Neurooncol 1999; 1:14-25.
6. Corn BW, Marcus SM, Topham A, et al. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997; 79:2409-2413.
7. Eby NL, Grufferman S, Flannelly CM, et al. Increasing incidence of primary brain lymphoma in the US. Cancer 1988; 62:2461-2465.
8. Rothova A, Ooijman F, Kerkhoff F, et al. Uveitis masquerade syndromes. Ophthalmology 2001; 108:386-399.
9. Read RW, Zamir E, Rao NA. Neoplastic masquerade syndromes. Surv Ophthalmol 2002; 47:81-124.
10. Barr CC, Green WR, Payne JW, et al. Intraocular reticulum-cell sarcoma: clinico-pathologic study of four cases and review of the literature. Surv Ophthalmol 1975; 19:224-239.
11. Rockwood EJ, Zakov N, Bay JW. Combined malignant lymphoma of the eye and CNS (reticulum-cell sarcoma). Report of three cases. J Neurosurg 1984; 61:369-374.
12. Qualman SJ, Mendelsohn G, Mann RB, et al. Intraocular lymphomas: natural history based on clinicopathologic study of eight cases and reviews of the literature. Cancer 1983; 52:878-886.
13. Char DH, Ljung BM, Miller T, et al. Primary intraocular lymphoma (ocular reticulum cell sarcoma). Diagnosis and management. Ophthalmology 1988; 95:625-630.
14. Cassoux N, Merle-Beral H, Leblond V, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 2000; 8:243-250.
15. Siegel MJ, Dalton J, Friedman AH, et al. Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol 1989; 73:342-346.
16. Buettner H, Bolling JP. Intravitreal large-cell lymphoma. Mayo Clin Proc 1993; 68:1011-1015.
17. DeAngelis LM, Yahalom J, Heinemann MH, et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990; 40:80-86.
18. Peterson K, Gordon KB, Heinemann MH, et al. The clinical spectrum of ocular lymphoma. Cancer 1993; 72:843-849.
19. Piessens WF, Schur PH, Moloney WC, et al. Lymphocyte surface immunoglobulins. Distribution and frequency in lymphoproliferative disorders. N Engl J Med 1973; 288:176-180.
20. Wilson DJ, Braziel R, Rosenbaum JT. Intraocular lymphoma: immunopathologic analysis of vitreous biopsy specimen. Arch Ophthalmol 1992; 110:1455-1458.
21. Levy-Clarke GA, Buggage RR, Shen D, et al. Human T-cell lymphotropic virus Type-1 associated T-cell leukemia/lymphoma masquerading as necrotizing retinal vasculitis. Ophthalmology 2002; 109:1717-1722.
22. Bardenstein DS. Intraocular lymphoma. Cancer Control 1998; 5:317-325.
23. Merchant A, Foster CS. Primary intraocular lymphoma. Int Ophthalmol Clin 1997; 37:101-105.
24. Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina 2002; 22:37-43.
25. Velez G, Smet MD, Whitcup SM, et al. Iris involvement in primary intraocular lymphoma: report of two cases and review of the literature. Surv Ophthalmol 2000; 44:518-526.
26. Streilein JW. Ocular immune privilege and tumors. In: Zierhut M, Jager MJ, Ksander BR, eds. Immunology of Ocular Tumors. Amsterdam: Swets & Zeitlinger; 2002:15-23.
27. Gill MK, Jampol LM. Variations in the presentation of primary intraocular lymphoma: case reports and a review. Surv Ophthalmol 2001; 45:463-471.
28. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 1999; 43:203-208.
29. Tuaillon N, Chan CC. Molecular analysis of primary central nervous system and primary intraocular lymphomas. Curr Mol Med 2001; 1:259-272.
30. Corboy JR, Garl PJ, Kleinschmidt-DeMasters BK. Human herpesvirus 8 DNA in CNS lymphomas from patients with and without AIDS. Neurology 1998; 50:335-340.
31. Chan CC, Shen DF, Buggage RR. Immunopathology and molecular biology of primary intraocular lymphoma. In: Zierhut M, Jager MJ, Ksander BR, eds. Immunology of Ocular Tumors. Amsterdam: Swets & Zeitlinger, 2002.
32. Chan CC, Shen DF, Whitcup SM, et al. Detection of human herpesvirus-8 and Epstein-Barr virus DNA in primary intraocular lymphomas. Blood 1999; 93:2749-2751.
33. Shen DF, Herbort CP, Tuaillon N, et al. Detection of Toxoplasma Gondii DNA in primary intraocular B-cell lymphoma. Mod Pathol 2001; 14:995-999.
34. Ongkosuwito JV, Lelij AVD, Bruinenberg M, et al. Increased presence of Epstein-Barr virus DNA in ocular fluid samples from HIV negative immunocompromised patients with uveitis. Br J Ophthalmol 1998; 82:245-251.
35. Mittra RA, Pulido JS, Hanson GA, et al. Primary ocular Epstein-Barr virus associated non-Hodgkin's lymphoma in a patient with AIDS. A clinicopathologic report. Retina 1999; 19:45-50.
36. Ursea R, Heinemann MK, Silverman RH, et al. Ophthalmic, ultrasonographic findings in primary central nervous system lymphoma with ocular involvement. Retina 1997; 17:118-123.
37. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma. Clinical features, diagnosis and outcome. Ophthamology 1999; 106:1805-1810.
38. Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Cur Opin Oncol 2001; 13:137-142.
39. Matsuo T, Yamaoka A, Shiraga F, et al. Two types of initial ocular manifestations in intraocular-central nervous system lymphoma. Retina 1998; 18:301-307.
40. Shah GK, Kleiner RC, Augsburger JJ, et al. Primary intraocular lymphoma seen with transient white fundus lesions simulating the multiple evanescent white dot syndrome. Arch Ophthalmol 2001; 119:617-620.
41. Rosenbaum TJ, MacCarty CS, Buettner TR. Uveitis and cerebral reticulum-cell sarcoma (large-cell lymphoma). J Neurosurg 1979; 50:660-664.
42. Soussain C, Merle-Béral H, Reux I, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 1996; 23:339-345.
43. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999; 43:237-239.
44. Levy-Clarke GA, Byrnes GA, Buggage RR, et al. Primary intraocular lymphoma diagnosed by fine needle aspiration biopsy of a subretinal lesion. Retina 2001; 21:281-284.
45. Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry. Am J Ophthalmol 1997; 124:362-372.
46. Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997; 115:1157-1160.
47. Akpek EK, Maca SM, Christen WG, et al. Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma. Ophthalmology 1999; 106:2291-2295.
48. White VA, Gascoyne RD, Paton KE. Use of polymerase chain reaction to detect B- and T-cell gene rearrangements in vitreous specimens from patients with intraocular lymphoma. Arch Ophthalmol 1999; 117:761-765.
49. Buggage RR, Velez G, Myers-Powell B, et al. Primary intraocular lymphoma with a low interleukin 10 to interleukin 6 ratio and heterogenous IgH gene rearrangement. Arch Ophthalmol 1999; 117:1239-1242.
50. Herrlinger U. Primary CNS lymphoma: findings outside the brain. J Neurooncol 1999; 43:227-230.
51. Burnstein SD, Kernohan JW, Uihlein A. Neoplasms of the reticuloendothelial system of the brain. Cancer 1963; 16:289-305.
52. Henry TM, Heffner RR, Dillard SH, et al. Primary malignant lymphomas of the central nervous system. Cancer 1974; 34:1293-1302.
53. Mendenhall NP, Thar TL, Agee OF, et al. Primary lymphoma of the central nervous system. Computerized tomography scan characteristics and treatment results for 12 cases. Cancer 1983; 52:1993-2000.
54. Pollack IF, Lunsford LD, Flickinger JC, et al. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989; 63:939-947.
55. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18:3144-3150.
56. Schlegel U, Schmidt-Wolf IGH, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sciences 2000; 181:1-12.
57. Henson JW, Yang J, Batchelor T. Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol 1999; 17:1329.
58. Batchelor TT, Kolak G, Ciorda R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003; 9:711-715.
59. Baumann MA, Ritch PS, Hande KR, et al. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 1986; 57:1273-1275.
60. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiation Oncology Biol Phys 1992; 23:9-17.
61. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma. A whole-brain disease? Neurology 2002; 59:1557-1562.
62. Brada M, Dearnaley D, Horwich A, et al. Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiation Oncology Biol Phys 1990; 18:787-792.
63. Shibamato Y, Sasai K, Oya N, et al. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study. J Neurooncol 1999; 42:162-167.
64. O'Neill BP, Wang CH, O'Fallon JR, et al. Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? a final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52. Int J Radiation Oncology Biol Phys 1999; 43:559-563.
65. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 1996; 14:556-564.
66. DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10:635-643.
67. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81:188-195.
68. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16:859-863.
69. Freilich RJ, Delattre JY, Monjour A, et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46:435-439.
70. Sandor V, Stark-Vancs V, Pearson D, et al. phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998; 16:3000-3006.
71. Lawler BE, Betensky R, Hochberg F, et al. Primary central nervous system lymphoma: the Massachusetts General Hospital. Proc Am Soc Clin Oncol 2002; 21:75a (Abstract #299).
72. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46:51-61.
73. Abrey LE, Moskowitz CH, Mason WP, et al. A phase II study of intensive methotrexate and cytarabine followed by high dose beam chemotherapy with autologous stem cell transplantation in patients with newly diagnosed primary central nervous system lymphoma. Proc Am Soc Clin Oncol 2001; 20:53a (Abstract #207).
74. Raizer JJ, DeAngelis LM, Zelenetz AD, et al. Activity of Rituximab in primary central nervous system lymphoma. Proc Am Soc Clin Oncol 2000; 19:166a (Abstract #642).
75. Ferreri AJM, Blay J-Y, Reni M, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphoma. Ann Oncol 2002; 13:531-538.
76. Ferreri AJM, Reni M, Dell'Oro S, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 2001; 60:134-140.
77. Khan RB, Shi W, Thaler HT, et al. is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002; 58:175-178.
78. Trudeau M, Shepherd F, Blackstein ME, et al. Intraocular lymphoma: report of three cases and review of literature. Am J Clin Oncol 1988; 11:126-130.
79. Margolis L, Fraser R, Lichter A, et al. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 1980; 45:688-692.
80. Valluri S, Moorthy RS, Khan A, et al. Combination treatment of intraocular lymphoma. Retina 1995; 15:125-129.
81. Sullivan SF, Dallow RL. Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential. Ann Ophthalmol 1977; 9:401-406.
82. Smet MD, Stark-Vancs V, Kohler DR, et al. Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996; 121:442-444.
83. Strauchen JA, Dalton J, Friedman AH. Chemotherapy in the management of intraocular lymphoma. Cancer 1989; 63:1918-1921.
84. Hormigo A, Abrey LE, DeAngelis LM. Treatment of ocular lymphoma. Proc Am Soc Clin Oncol 2002; 21:75a (Abstract #297).
85. Hormigo A, DeAngelis LM. Treatment of primary central nervous system lymphoma in immunocompetent patients. In: Batchelor T, ed. Lymphoma of the Nervous System. Boston, Mass: Elsevier Science. In press.
86. Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997; 115:1152-1156.
87. Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999; 83:448-451.
88. Velez G, Boldt HC, Whitcup SM, et al. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers 2002; 33:329-333.
89. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109:1709-1716.
90. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001; 119:1518-1524.